Extending the utility of IGS as potential PD whole-blood biomarkers, we uncovered PATL2 as the top risk gene in terms of classifier performance and found its enrichment in pathological T lymphocyte subsets (cytotoxic CD4+ and terminal effector CD8+ subsets) which are both expanded in PD pathogenesis. This evidence concerns the gene CD4 and Parkinson disease.